Sargramostim

Identification

Name
Sargramostim
Accession Number
DB00020 / 5TAA004E22
Groups
Leukine
Description

Sargramostim is a human recombinant granulocyte macrophage colony-stimulating element (GM-CSF) expressed in yeast. it is a glycoprotein this is 127 residues. Substitution of Leu23 results in a difference from native protein.

Pharmacology

Pharmacodynamics

Sargramostim is used in the treatment of bone marrow transplant recipients or those exposed to chemotherapy an recovering from acut myelogenous leukemia, Leukine or GM-CSF is a hematopoietic growth factor which stimulates the survival, clonal expansion (proliferation) and differentiation of hematopoietic progenitor cells. GM-CSF is also capable of activating mature granulocytes and macrophages. After a bone marrow transplant or chemotherapy, patients have a reduced capacity to produce red and white blood cells. Supplementing them with external sources of GM-CSF helps bring the level of neutrophils back to normal so that they can better fight infections.

Indication

For the treatment of cancer and bone marrow transplant

Action

Sargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway. This leads to the production of hemopoietic cells and neutrophils